Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Income from Continuing Operations (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Income from Continuing Operations for 4 consecutive years, with 25442000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 39.38% to 25442000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 101337000.0 through Dec 2025, down 19.75% year-over-year, with the annual reading at 101337000.0 for FY2025, 19.75% down from the prior year.
  • Income from Continuing Operations hit 25442000.0 in Q4 2025 for Taysha Gene Therapies, up from 30870000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15038000.0 in Q4 2023 to a low of 55072000.0 in Q4 2022.
  • Historically, Income from Continuing Operations has averaged 26572187.5 across 4 years, with a median of 24208000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 72.69% in 2023 and later crashed 43.36% in 2024.
  • Year by year, Income from Continuing Operations stood at 55072000.0 in 2022, then surged by 72.69% to 15038000.0 in 2023, then fell by 21.39% to 18254000.0 in 2024, then crashed by 39.38% to 25442000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TSHA at 25442000.0 in Q4 2025, 30870000.0 in Q3 2025, and 24911000.0 in Q2 2025.